Milner Therapeutics Institute and Consortium

Milner Therapeutics Institute, Pfizer partner

Friday, January 20, 2017

The Milner Therapeutics Institute has announced Pfizer as a partner to the Milner Therapeutics Consortium. Pfizer has agreed to join the Consortium, which enables the efficient transfer of materials between industry and academia and allocation of funds for partnering opportunities in Cambridge. Dr. Ron Newbold, vice president, External R&D Innovation at Pfizer, will join the Milner Innovation Board alongside representatives from Astex, AstraZeneca, GlaxoSmithKline, Shionogi, MedImmune, University of Cambridge, Babraham Institute and Sanger Institute.

[Read More]

The CenterWatch Weekly, August 22, 2016

Monday, August 22, 2016

As necessity for real-world evidence rises, PPD acquires of Evidera

Pharmaceutical Product Development (PPD) has agreed to buy Evidera, a Maryland-based company that provides evidence-based solutions for the healthcare industry, as demand rises for research that shows the effectiveness and value of new medicines in real world settings.

[Read More]